ConductScience.org, home

Gene · 10733

PLK4: polo like kinase 4

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. PLK4: polo like kinase 4. Genes, record 10733. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10733

On this page

Gene

Symbol
PLK4
HGNC
Name
polo like kinase 4
HGNC
NCBI Gene ID
10733
NCBI Gene
HGNC ID
HGNC:11397
HGNC
Ensembl
ENSG00000142731
NCBI Gene
Aliases
MCCRP2, SAK, STK18, Sak
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O00444Serine/threonine-protein kinase PLK497019Ensembl, GeneID, HGNC

Source UniProt

Patents20

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026515744 A2026-05-19106O00444Espacenet
EP 4641202 A22025-10-294637O00444Espacenet
KR 1020250017231 A2025-02-044637O00444Espacenet
WO 2024214081 A12024-10-17106O00444Espacenet
JP 2024123008 A2024-09-107748O00444Espacenet
US 11446398 B22022-09-2064478O00444Espacenet
JP 2022524081 A2022-04-27167449O00444Espacenet
US 10752612 B22020-08-252O00444Espacenet
JP 2020062004 A2020-04-231137O00444Espacenet
US 10501513 B22019-12-107748O00444Espacenet

1 to 10 of 20

See all 20 patents

Drugs3

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
CFI-400945CHEMBL4297462Serine/threonine-protein kinase PLK4 inhibitorINHIBITORChEMBL
OCIFISERTIBCHEMBL3408947Serine/threonine-protein kinase PLK4 inhibitorINHIBITORChEMBL
RG-1530CHEMBL1980391Serine/threonine-protein kinase PLK4 inhibitorINHIBITORChEMBL

Trials5

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT04730258CFI-400945PHASE1/PHASE2ClinicalTrials.gov
NCT04176848CFI-400945PHASE22024-08-09ClinicalTrials.gov
NCT03624543CFI-400945PHASE2ClinicalTrials.gov
NCT03385655CFI-400945PHASE2ClinicalTrials.gov
NCT03187288CFI-400945PHASE1ClinicalTrials.gov

NIH grants1,134

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePLK4 papersNewest fiscal year
P30CA008748Cancer Center Support Grant182025
P30CA014520UW Comprehensive Cancer Center Support132025
P30CA023074University of Arizona Cancer Center - Cancer Center Support Grant112025
ZIABC011459Control of centrosome biogenesis112025
R01GM074207Analysis of Centrosome Dynamics92025
R01GM088253Template-based replication of the centriole organelle92025
P30CA016672Cancer Center Support Grant82025
U54CA163071(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership #62025
P30CA060553The Robert H. Lurie Comprehensive Cancer Center52025
P30CA086862Cancer Center Support Grant52025

1 to 10 of 1,134Source NIH's project files

See all 1,134 nih grants

Papers2,106

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Skeletal muscle dedifferentiation requires centrosomes.NPJ Regen Med202642786221PubTator, text miningPubMed
The Centriole Biogenesis Cycle: Temporal Mechanisms, Autonomy and Coupling to the Cell Cycle and Other Cellular Clocks.Adv Exp Med Biol202642782439PubTator, text miningPubMed
CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.Cancer Lett202642762966PubTator, text miningPubMed
Divergent microtubule-organizing center strategies in mammalian gametogenesis.Trends Open202642761981PubTator, text miningPubMed
Design, Synthesis, and Biological Activity Evaluation of Quinazoline-Based PLK4 Inhibitors.Biomedicines202642652193PubTator, text miningPubMed
Centriolar satellites regulate CEP350 mRNA stability and centrosome amplification.Mol Biol Cell202642555824PubTator, text miningPubMed
Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37-Amplified Neuroblastoma.J Med Chem202642463132PubTator, text miningPubMed
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma.NPJ Precis Oncol202642432132PubTator, text miningPubMed
Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification.Cancer Cell Int202642316241PubTator, text miningPubMed
Two distinct causes contribute to the low efficiency of human pre-implantation development.Cell202642276044PubTator, text miningPubMed

1 to 10 of 2,106

See all 2,106 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/10733

GET https://conductscience.org/api/genes/v1/10733/patents